Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC6 | Q9Y210 | 5/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | NEK2 | P51955 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30420485 | 0.85 | NR1H3 (0.43) | TRPC6 | |
| SCHEMBL25264927 | 0.85 | CHRM4 (0.40) | CHRM4CHRM2CHRM1 | |
| SCHEMBL25189280 | 0.85 | CHRM4 (0.40) | CHRM4CHRM2CHRM1 | |
| SCHEMBL19096956 | 0.77 | USP30 (0.41) | OPRK1CHRM4CHRM2CHRM1 | |
| SCHEMBL20954167 | 0.77 | USP30 (0.41) | OPRK1CHRM4CHRM2CHRM1 | |
| SCHEMBL20954154 | 0.77 | USP30 (0.41) | OPRK1CHRM4CHRM2CHRM1 | |
| SCHEMBL16570434 | 0.75 | GFER (0.47) | TRPC6OPRK1MAPK1 | |
| SCHEMBL25197760 | 0.75 | IDO1 (0.40) | TRPC6MAPK1 | |
| SCHEMBL25188137 | 0.74 | JAK3 (0.42) | TRPC6SLC6A9JAK3 | |
| SCHEMBL19096999 | 0.73 | USP30 (0.43) | OPRK1CHRM4CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023086959-A1 | FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |